RU2012148214A - Композиции и способы для лечения нарушений зрения - Google Patents
Композиции и способы для лечения нарушений зрения Download PDFInfo
- Publication number
- RU2012148214A RU2012148214A RU2012148214/15A RU2012148214A RU2012148214A RU 2012148214 A RU2012148214 A RU 2012148214A RU 2012148214/15 A RU2012148214/15 A RU 2012148214/15A RU 2012148214 A RU2012148214 A RU 2012148214A RU 2012148214 A RU2012148214 A RU 2012148214A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- substituted
- group
- retinal
- oil
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 10
- 239000000203 mixture Substances 0.000 title claims 14
- 208000029257 vision disease Diseases 0.000 title claims 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 20
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 20
- 239000001257 hydrogen Substances 0.000 claims abstract 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 20
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 16
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000003118 aryl group Chemical group 0.000 claims abstract 8
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims abstract 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract 8
- 229940124530 sulfonamide Drugs 0.000 claims abstract 8
- 150000003456 sulfonamides Chemical class 0.000 claims abstract 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims abstract 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims abstract 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract 4
- 125000004149 thio group Chemical group *S* 0.000 claims abstract 4
- 208000001344 Macular Edema Diseases 0.000 claims abstract 3
- 206010025415 Macular oedema Diseases 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 3
- 201000010230 macular retinal edema Diseases 0.000 claims abstract 3
- 208000008069 Geographic Atrophy Diseases 0.000 claims abstract 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims abstract 2
- 208000030533 eye disease Diseases 0.000 claims abstract 2
- 230000002207 retinal effect Effects 0.000 claims 9
- 208000017442 Retinal disease Diseases 0.000 claims 6
- 206010038923 Retinopathy Diseases 0.000 claims 5
- 201000004569 Blindness Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 4
- 235000019198 oils Nutrition 0.000 claims 4
- 235000002639 sodium chloride Nutrition 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000002367 Retinal Perforations Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 206010047571 Visual impairment Diseases 0.000 claims 3
- 210000000981 epithelium Anatomy 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 210000001927 retinal artery Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 230000004393 visual impairment Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000009487 Amblyopia Diseases 0.000 claims 2
- 206010005177 Blindness cortical Diseases 0.000 claims 2
- 208000014882 Carotid artery disease Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 201000002563 Histoplasmosis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 235000019483 Peanut oil Nutrition 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims 2
- 208000027076 Uveal disease Diseases 0.000 claims 2
- 208000029977 White Dot Syndromes Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 235000005687 corn oil Nutrition 0.000 claims 2
- 239000002285 corn oil Substances 0.000 claims 2
- 208000009153 cortical blindness Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 239000000312 peanut oil Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 210000001525 retina Anatomy 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 claims 1
- 235000019489 Almond oil Nutrition 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 240000000467 Carum carvi Species 0.000 claims 1
- 235000005747 Carum carvi Nutrition 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000033379 Chorioretinopathy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010070957 Choroidal haemangioma Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 244000037364 Cinnamomum aromaticum Species 0.000 claims 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 208000001351 Epiretinal Membrane Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010058558 Hypoperfusion Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 208000032578 Inherited retinal disease Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000009857 Microaneurysm Diseases 0.000 claims 1
- 208000010164 Multifocal Choroiditis Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000006123 Myiasis Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010064997 Necrotising retinitis Diseases 0.000 claims 1
- 208000001140 Night Blindness Diseases 0.000 claims 1
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims 1
- 208000004788 Pars Planitis Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 235000019484 Rapeseed oil Nutrition 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000032430 Retinal dystrophy Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010038915 Retinitis viral Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 235000019485 Safflower oil Nutrition 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000014286 Serpiginous choroiditis Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000036038 Subretinal fibrosis Diseases 0.000 claims 1
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 206010044269 Toxocariasis Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 208000023564 acute macular neuroretinopathy Diseases 0.000 claims 1
- 239000008168 almond oil Substances 0.000 claims 1
- 229920006321 anionic cellulose Polymers 0.000 claims 1
- 239000010617 anise oil Substances 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 208000027129 choroid disease Diseases 0.000 claims 1
- 239000010630 cinnamon oil Substances 0.000 claims 1
- 239000010634 clove oil Substances 0.000 claims 1
- 201000008615 cone dystrophy Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 239000010642 eucalyptus oil Substances 0.000 claims 1
- 229940044949 eucalyptus oil Drugs 0.000 claims 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 claims 1
- 201000006321 fundus dystrophy Diseases 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000000944 linseed oil Substances 0.000 claims 1
- 235000021388 linseed oil Nutrition 0.000 claims 1
- 230000027928 long-term synaptic potentiation Effects 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- XWCKCINXPIGGEB-UHFFFAOYSA-N oxadiazol-5-yl(piperidin-1-yl)methanone Chemical compound C=1N=NOC=1C(=O)N1CCCCC1 XWCKCINXPIGGEB-UHFFFAOYSA-N 0.000 claims 1
- 235000019477 peppermint oil Nutrition 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 201000004849 posterior scleritis Diseases 0.000 claims 1
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 210000000977 primary visual cortex Anatomy 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 1
- 210000001957 retinal vein Anatomy 0.000 claims 1
- 239000010668 rosemary oil Substances 0.000 claims 1
- 229940058206 rosemary oil Drugs 0.000 claims 1
- 235000005713 safflower oil Nutrition 0.000 claims 1
- 239000003813 safflower oil Substances 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims 1
- 229940001474 sodium thiosulfate Drugs 0.000 claims 1
- 235000019345 sodium thiosulphate Nutrition 0.000 claims 1
- 239000003549 soybean oil Substances 0.000 claims 1
- 235000012424 soybean oil Nutrition 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000013517 stratification Methods 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 210000000857 visual cortex Anatomy 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 210000003161 choroid Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 0 C*(*(*)N1N=Nc(cc(c(I[C@](*)C(C2)=C*)c3)C2=O)c3C1=O)C1(*)*(*)C1* Chemical compound C*(*(*)N1N=Nc(cc(c(I[C@](*)C(C2)=C*)c3)C2=O)c3C1=O)C1(*)*(*)C1* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32463210P | 2010-04-15 | 2010-04-15 | |
| US61/324,632 | 2010-04-15 | ||
| PCT/US2011/032325 WO2011130411A1 (en) | 2010-04-15 | 2011-04-13 | Compositions and methods for treating visual disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012148214A true RU2012148214A (ru) | 2014-05-20 |
Family
ID=44009992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012148214/15A RU2012148214A (ru) | 2010-04-15 | 2011-04-13 | Композиции и способы для лечения нарушений зрения |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110257186A1 (enExample) |
| EP (1) | EP2558100A1 (enExample) |
| JP (1) | JP2013523892A (enExample) |
| KR (1) | KR20130092976A (enExample) |
| AU (1) | AU2011239683A1 (enExample) |
| CA (1) | CA2796345A1 (enExample) |
| RU (1) | RU2012148214A (enExample) |
| WO (1) | WO2011130411A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201600127037A1 (it) * | 2016-12-15 | 2018-06-15 | Oftalab S R L | Soluzione oftalmica di verde di lissamina e suo uso in oftalmologia |
| CN109908327A (zh) * | 2019-03-12 | 2019-06-21 | 广州陈锦济生物科技有限公司 | 一种用于治疗近视的眼药水及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| KR20050094840A (ko) * | 2003-01-13 | 2005-09-28 | 코텍스 파마슈티칼스, 인크. | 수면 부족 및 스트레스로 인한 인식 저하의 치료방법 |
| CA2649844C (en) * | 2006-04-20 | 2011-07-05 | The Regents Of The University Of California | Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression |
| US20080139472A1 (en) * | 2006-10-06 | 2008-06-12 | The Regents Of The University Of California | Upregulating bdnf levels to mitigate mental retardation |
| CA2674321A1 (en) * | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| AP2502A (en) * | 2007-01-03 | 2012-10-23 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses |
| AU2008301884B2 (en) * | 2007-09-20 | 2012-12-20 | Cortex Pharmaceuticals, Inc. | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
-
2011
- 2011-04-12 US US13/085,241 patent/US20110257186A1/en not_active Abandoned
- 2011-04-13 KR KR1020127029867A patent/KR20130092976A/ko not_active Withdrawn
- 2011-04-13 RU RU2012148214/15A patent/RU2012148214A/ru not_active Application Discontinuation
- 2011-04-13 JP JP2013505098A patent/JP2013523892A/ja active Pending
- 2011-04-13 EP EP11715842A patent/EP2558100A1/en not_active Withdrawn
- 2011-04-13 CA CA2796345A patent/CA2796345A1/en not_active Abandoned
- 2011-04-13 WO PCT/US2011/032325 patent/WO2011130411A1/en not_active Ceased
- 2011-04-13 AU AU2011239683A patent/AU2011239683A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130092976A (ko) | 2013-08-21 |
| EP2558100A1 (en) | 2013-02-20 |
| CA2796345A1 (en) | 2011-10-20 |
| US20110257186A1 (en) | 2011-10-20 |
| AU2011239683A1 (en) | 2012-11-08 |
| JP2013523892A (ja) | 2013-06-17 |
| WO2011130411A1 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3045733C (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| ES2399314T3 (es) | Gamma lactamas sustituidas como agentes terapeúticos | |
| US7105512B2 (en) | Ophthalmic aqueous pharmaceutical preparation | |
| JP2018529693A5 (enExample) | ||
| JP2019514956A5 (enExample) | ||
| CA2491313A1 (en) | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use | |
| JP2018514590A5 (enExample) | ||
| RU2020118178A (ru) | Лекарственные средства и композиции для доставки в глаз | |
| RU2009145939A (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
| RU2012148214A (ru) | Композиции и способы для лечения нарушений зрения | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| WO2005055926A3 (en) | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | |
| JP2013523892A5 (enExample) | ||
| WO2020041344A4 (en) | Methods and compositions for drugs to treat ophthalmic diseases | |
| JP2018510855A5 (enExample) | ||
| US20170172959A1 (en) | D-serine for the treatment of visual system disorders | |
| JP6616403B2 (ja) | 一酸化窒素供与カルノシン化合物 | |
| KR20120081585A (ko) | 안질환을 치료하기 위한 이소티오졸 | |
| RU2016124102A (ru) | Способ лечения офтальмологических расстройств с помощью соединений, обнаруженных в секретах железы мигательной перепонки | |
| WO2008024846A2 (en) | Brimonidine and timolol compositions | |
| US20080051406A1 (en) | Brimonidine and timolol compositions | |
| ES2452026T3 (es) | Prostaglandinas y análogos como agentes para disminuir la presión intraocular | |
| ES2435554T3 (es) | Compuestos de prostaglandina terapéuticos utilizados como agentes hipotensores oculares | |
| WO2008094958A1 (en) | Thiophene derivatives useful as medicaments for treating ocular hypertension | |
| RU2014106328A (ru) | Фармацевтические композиции, содержащие 4-бром-n-(имидазолидин-2-илиден)-1н-бензимидазол-5-амин для лечения заболеваний сетчатки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150827 |